Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
Stockhouse15d
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, ...
BioSpace15d
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene ...
manilatimes23d
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR
CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...
The West Australian25d
Rugby stars hit Scarborough Beach ahead of HSBC SVNS at HBF Park in Perth
The Australian women’s side face off against China on Friday afternoon. The HSBC SVNS Series will again take over HBF Park for three days from Friday through to Sunday. It marks the second time the ...
Business News28d
HBF, Cimic legal dispute continues
HBF’s legal action against the developers behind Kings Square, including Cimic Group and companies linked to Seven Network, continues in the state’s highest court. Cimic and the other entities denied ...